Ethanol Extract of Moringa Propolis Modulates Pro-Inflammatory Cytokines in Mice with Acute Toxoplasmosis
Summary
No summary yet. VIRAT can read this paper and write a plain-language summary of its aim, methods, key findings and limitations.
Summarise with VIRAT Free to try with your Science Catalogs account.Abstract
Toxoplasma gondii can cause an increase the cytokine, increased cytokine pro-inflamation can cause cell damage.Natural products such as propolis can be choice for treatment toxoplasmosis for reduce cytokine proinflamation (TNF-α and IFN-γ).We compare the amount of cytokines in each treatment group.We employed flow cytometry to assess cytokine expression.We used 36 mice were divided into six group, group one mice were not infected and treated as negative control, groups 2 to 6 allmice were infected T. gondii with 100 tachyzoites.Group 2 mice were infected but not treated, group 3 mice were infected and treated with orally cotrimoxazole 40 mg/kg body weight, group 4 mice were infected and treated with Ethanol Extract Propolis (EEP) 1 mg/mouse, group 5 mice were infected and treated with EEP 2 mg/mouse, and group 6 mice were infected and treated with EEP 4 mg/mouse one day after infection for three days.We observed cytokines in mice exposed to Toxoplasma gondii.Statistical analysis was performed with one-way ANOVA and Duncan Multiple Range Test in SPSS 30 software.Results showed that EEP (1-4 mg) can reduce reduced levels of pro-inflammatory cytokines (TNF-α, IFN-γ) no significant differences caspase-3 in all treatments, TNF-α and IFN-γ from the results we obtained showed lower values when compared to the group of toxoplasmosis mice treated using cotrimoxazole.The best choice for toxoplasmosis therapy using EEP is in group P6 with a dose of 4 mg.
Fields of Study & Subjects
Toxoplasma gondii Research Studies
Bee Products Chemical Analysis
Malaria Research and Control
Publication details
- Journal / source
- Advances in Animal and Veterinary Sciences
- Volume
- 14
- Issue
- 4
- Publication date
- 31 March 2026
- Language
- EN